Biora Therapeutics, a clinical-stage biotechnology company, has announced the offering of 5,454,548 shares of its common stock at a price of $1.10 per share to certain institutional investors. The offering is made pursuant to a prospectus supplement and the accompanying prospectus dated August 6, 2021. Concurrently, Biora Therapeutics is issuing warrants to purchase an additional 5,454,548 shares of common stock, representing 100% of the shares purchased in the offering. These warrants will be exercisable upon stockholder approval at the same price of $1.10 per share and will have a term of five years from the date of approval. The warrants and the shares issuable upon exercise are not being registered under the Securities Act of 1933, as amended, and are being offered pursuant to an exemption provided...Show More

Biora Therapeutics, a clinical-stage biotechnology company, has announced the offering of 5,454,548 shares of its common stock at a price of $1.10 per share to certain institutional investors. The offering is made pursuant to a prospectus supplement and the accompanying prospectus dated August 6, 2021. Concurrently, Biora Therapeutics is issuing warrants to purchase an additional 5,454,548 shares of common stock, representing 100% of the shares purchased in the offering. These warrants will be exercisable upon stockholder approval at the same price of $1.10 per share and will have a term of five years from the date of approval. The warrants and the shares issuable upon exercise are not being registered under the Securities Act of 1933, as amended, and are being offered pursuant to an exemption provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder. The warrants will not be listed for trading on any national securities exchange, and each purchaser will be an accredited investor. Biora's common stock is currently traded on the Nasdaq Global Market under the symbol 'BIOR.' The last reported sale price for the common stock on Nasdaq was $1.10 per share as of March 28, 2024. H.C. Wainwright & Co., LLC has been retained as the exclusive placement agent for the securities offered. The placement agent has agreed to use its reasonable best efforts to sell the securities offered. The offering is expected to close on or about April 3, 2024.